Your Article Summary
See Latest ArticlesTrends in RA patients' adherence to subcutaneous anti-TNF therapies and costs
Current Medical Research and Opinion, 06/24/09
Borah BJ et al. – Study reports that etanercept (ETA) users had longer treatment duration, were more likely to adhere to their medication regimen and had lower rheumatoid arthritis (RA)-related pharmacy and RA-related total costs compared with adalimumab (ADA) users.
Methods- Main objectives of study were:
- To examine adherence to ADA and ETA and health care costs in RA pts, and
- To explore the association between adherence, utilization and costs
- RA pts treated with etanercept or adalimumab during Jan 2005-Dec 2005 were identified
- Patient adherence and costs were assessed during the 1 yr post-index period (first dispensing date)
- Nonadherence was modeled using logistic regression
- Hazard ratios (HR) comparing time to discontinuation were estimated using Cox proportional hazard (PH) models
- Compared with ADA users, ETA users had longer average treatment duration
- Unadjusted adherence rates for naïve and existing users were 63% and 70% (ADA), and 65% and 73% (ETA)
- Compared with ETA users, ADA users were more likely to be nonadherent
- Existing ADA users were more likely to discontinue their medication than existing ETA users
- Compared with ADA users, ETA users had lower RA-related pharmacy costs and RA-related total costs
Today in Physician/Patient Trends...keeping you current
Receive free subspecialty "5-minute updates" via email
Predicting age at onset of menopause: Testing the "adaptive onset" hypothesis
Maturitas, 11/11/09
Trends in prescribing and self-poisoning in relation to UK regulatory authority warnings against use of SSRI antidepressants in under-18-year-olds
British Journal of Clinical Pharmacology, 11/02/09
Urinary Diversion Trends at a High Volume, Single American Tertiary Care Center
The Journal of Urology, 11/02/09